David Eansor

2018

In 2018, David Eansor earned a total compensation of $1.6M as Senior Vice President Biotechnology at Bio-Techne, a 18% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$403,181
Option Awards$543,753
Salary$455,000
Stock Awards$181,248
Other$8,100
Total$1,591,282

Eansor received $543.8K in option awards, accounting for 34% of the total pay in 2018.

Eansor also received $403.2K in non-equity incentive plan, $455K in salary, $181.2K in stock awards and $8.1K in other compensation.

Rankings

In 2018, David Eansor's compensation ranked 6,879th out of 14,244 executives tracked by ExecPay. In other words, Eansor earned more than 51.7% of executives.

ClassificationRankingPercentile
All
6,879
out of 14,244
52nd
Division
Manufacturing
2,637
out of 5,758
54th
Major group
Chemicals And Allied Products
993
out of 2,119
53rd
Industry group
Drugs
834
out of 1,808
54th
Industry
Biological Products, Except Diagnostic Substances
160
out of 339
53rd
Source: SEC filing on September 9, 2019.

Eansor's colleagues

We found four more compensation records of executives who worked with David Eansor at Bio-Techne in 2018.

2018

Charles Kummeth

Bio-Techne

Chief Executive Officer

2018

James Hippel

Bio-Techne

Chief Financial Officer

2018

Brenda Furlow

Bio-Techne

General Counsel

2018

Kim Kelderman

Bio-Techne

President, Diagnostics and Genomics

News

You may also like